FivePrime scores $15M in collaboration pact

FivePrime Therapeutics has struck a deal to collaborate with Centocor Research and Development (a Johnson & Johnson company) on the development of new therapies for osteoarthritis and pulmonary fibrosis. Under the collaboration, FivePrime will screen its protein library against cell-based assays directed to osteoarthritis and fibrosis and Centocor will have exclusive rights to the proteins and targets identified in these screens. FivePrime will receive an upfront payment of $15 million in cash, an equity investment by J&J Development Corporation and two years research funding from Centocor. Centocor will have exclusive worldwide rights to develop and commercialize products and targets discovered during the research term in exchange for future milestones and royalties. Further details of the agreement weren't disclosed.

"With Centocor as a partner in these disease areas, we should be able to move the products of our discovery platform into clinical trials faster and more effectively," commented Lewis T. "Rusty" Williams, FivePrime's founder and executive chairman. FivePrime was a 2004 Fierce 15 company.

- check out the release on the deal

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.